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Abstract 
Background.In the last years, new techniques, drugs and devices have been introduced in the 
current practice of primary angioplasty (PPCI) and validated by pivotal studies The objective of our 
study was to evaluate if these studies have led to significant changes on the current practice of 
primary PCI in our center.  
Methods. From March 2003 to December 2013 1980 patients with ST-segment elevation 
myocardial infarction underwent PPCI within 12-hours of onset of symptoms. We considered 2 
periods of our activity:  from 2003 to 2009 (P1) with 1078 patients and from 2010 to 2013 (P2) with 
902 patients, and compared them in terms of pharmacological and arterial access strategies and of 
devices utilization.  
Results. In P2 there was a significant increase of radial access (34.1% vs 1.5, p<0.001), as well as 
of the use of bivalirudin (22.7% vs 0.5%, p<0.001) and of new antiplatelet drugs (prasugrel or 
ticagrelor) (18.3% vs 0%, p<0.001) whereas the use of GP IIb-IIIa and of intraaortic balloon pump 
significantly decreased (from 82.3% to 52%, p<0.001 and from 17% to 7.5%, p<0.001 
respectively). In the P2 there was a significant increase of the procedural efficacy (97.2% vs 95.1%, 
p=0.01) that persisted after the logistic regression adjustment (OR 2.09, CI 95%, 1.04-4.21).  
Conclusions. Our study shows that in the last years, in a high-PCI center, after the publication of 
pivotal randomized trial and nationwide registries, there were significant changes in the PPCI 
current practice that could have had an impact on procedural efficacy.  
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Introduction 
Primary angioplasty (PPCI) has been demonstrated to be superior to fibrinolytic therapy in the 
management of patients with ST-segment elevation myocardial infarction (STEMI) 
1–3
 becoming 
the leading  treatment in this setting 
4
. In the last years, new drugs and devices have been introduced 
in the practice of PPCI which have been validated by pivotal studies. In particular, the Radial versus 
femoral access for coronary angiography and intervention in patients with acute coronary 
syndromes (RIVAL) and the Radial Versus Femoral Randomized Investigation in ST-Elevation 
Acute Coronary Syndrome (RIFLE-STEACS) randomized trials 
5,6
, have demonstrated that the  
transradial artery access (TRA) can reduce bleeding complications and even the 30-days mortality, 
compared to transfemoral artery access (TFA) in patients with STEMI. The same result was 
achieved by a direct thrombin inhibitor, bivalirudin, in the Harmonizing Outcomes with 
Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial 
7,8
, compared 
to unfractioned heparin (UFH) plus Glicoproteins (GP) IIb-IIIa inhibitors, and  these advantages 
were extended at 12 months. Finally, the Plateler Inhibition and Patient Outcomes (PLATO) and the 
Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in 
Myocardial Infarction 38 (TRITON-TIMI 38) 
9,10
 showed that  new antiplatelet drugs, ticagrelor and 
prasugrel respectively, reduced the cardiovascular and the total mortality compared to clopidogrel, 
even if they increased the bleeding complications at least in more frail patients. Furthermore, the 
Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) randomized trial 
11
 did not show any 
superiority of GP IIb-IIIa over UFH in terms of reduction of infarct size. As a result, the 2010 
European Guidelines on revascularization put the bivalirudin use, as well as that of new antiplatelet 
drugs in class I, whereas they downgraded the upstream use of GP IIb-IIIa inhibitors in class III 
12
. 
Yet, the net benefit effect demonstrated in randomized clinical trials (RCT) might not be the same 
as that observed in different clinical settings, because most RCT  focus on the assessment of a 
single maneuver, and the investigated population might not be representative of the real-world 
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practice 
13
. Therefore, large observational registries are needed in order to assessing treatment 
effectiveness in patients encountered in day-to-day clinical practice, undergoing everyday therapy. 
Aim of this large observational registry is to assess the impact of these recent pivotal studies in 
terms of changing the current practice of PPCI in an high volume hospital. 
Methods 
The Infermi Hospital in Rivoli, Italy, is a community hospital without cardiac surgery backup with 
a high volume catheterization laboratory (>900 PCI and >200 PPCI per year), which provides a 24-
hour PCI service and is only 14 Km far from the nearest hospital with cardiac surgery backup. In 
2008, the catchment area increased up to 583,000 inhabitants, including another hospital with 
intensive cardiac care unit, but without PCI facility.  
Study population 
The data of all consecutive patients with STEMI admitted to the Infermi Hospital hospital between 
march 2003 and December 2013 and treated by primary PCI within 12 hours of symptom onset 
were reviewed. Demographic, clinical and procedural data were prospectively collected in a 
dedicated database (Cardioplanet V.3.0.8, Ebit Aet S.p.A., Genoa, Italy).  
The study protocol was approved by the Ethics Committee of our Institution (ASL 103, Piemonte 
Region, Italy) and informed consent was obtained in all patients.  
Study definitions, procedures and medications 
STEMI was defined as typical chest pain lasting more than 30 minutes associated with >0.1 mV 
ST-segment elevation in ≥2 contiguous electrocardiogram (ECG) leads or with new left bundle 
branch block. Door-to-balloon (D2B) time was defined as the time interval from arrival to the 
hospital (the initial referral hospital for transferred patients) to the first balloon inflation during 
PPCI. Total ischemic time was defined as the time interval from symptom onset to first balloon 
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inflation during PPCI. Lesion characteristics were evaluated according to the ACC/AHA 
classification 
14
.  
All STEMI patients who complained symptoms for ≤12 hours were immediately transferred to the 
catheterization laboratory for urgent coronary angiography.  
The indications to manual thrombus aspiration (TA) were driven by few parameters evaluated after 
diagnostic angiography as already reported 
15
: a) visual estimation of infarct related artery (IRA) 
diameter ≥3 mm; b) the absence of severe proximal tortuosity and/or calcifications; c) complete 
vessel occlusion with distal convex contrast stain and the presence of visual thrombus in case of a 
patent IRA. However, the final decision to its use of TA as well as of intra-aortic balloon pump 
(IABP) support was left to the discretion of the operator.  
A successful procedure was defined as a residual stenosis of treated vessels <30% associated with a 
Thrombolysis In Myocardial Infarction (TIMI) 3 grade flow 
16
.  
All patients were routinely given aspirin (325 mg upon arrival, and then 100 mg daily) and an 
intravenous bolus of UFH (5000 U) in ambulance or in emergency room. The use of either 
bivalirudin (bolus of 0.75 mg/Kg and 1.75 mg/Kg/h thereafter), or UFH (100 U/Kg or 60 U/Kg if 
abciximab was used) or abciximab (bolus of 0.25 mg/Kg and 0.125 mcg/Kg/min for 12 hours) was 
left to the discretion of the operator. UFH therapy was stopped after the procedure, but, in case of 
IABP use, it was continued until its removal. When used, abciximab infusion was continued for 12 
hours after the procedure. At the beginning of this use, we used to stop bivalirudin at the end of the 
procedure, but, since the publication of the European Ambulance Acute Coronary Syndrome 
Angiography (EUROMAX) randomized trial 17, it has been continued for 4 hours thereafter.  
Until 2010, clopidogrel (loading dose 300 or 600 mg and 75 mg daily thereafter) was given as 
second antiplatelet drug but, afterwards, prasugrel (60 mg loading dose and 10 mg daily thereafter) 
and ticagrelor (180 mg loading dose and 90 mg bid thereafter) were used as well. Beta-adrenergic 
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blockers, ACE inhibitors and statins were used as in-hospital standard therapy, if not 
contraindicated.  
Study Objectives 
Two time-frames of activity were considered: from 2003 up to the end of  2009 (P1) and from 2010 
up to the end of 2013 (P2). We chose this cut-off since our current practice did not have significant 
modifications up to the end of 2009 
18
, whereas at the beginning of 2010, bivalirudin and the new 
antiplatelet drugs became available in our center. Furthermore, in the same year, a TRA 
intervention program in the urgency setting has been set up. We also took into account the 
differences in using TA, drug-eluting stents (DES) as well as of IABP support.  
The aim of the study was to evaluate the changes in procedural characteristics in terms of vascular 
access, pharmacological treatment and device utilization. Thus we investigated the impact of these 
changes on procedural efficacy rate (defined as TIMI III grade flow and residual stenosis <30%) 
and in terms of in-hospital outcomes, defined as Major Cardiovascular Cardiac Events (MACE),  
i.e.  death, recurrent myocardial infarction, stroke and target vessel revascularization. The rate of 
definite and probable stent thrombosis (ST) defined according to the Academic Research 
Consortium 
19
 and of bleeding complications acccording to Bleeding Academic Research 
Consortium (BARC) classification 
20
 were also taken into account. 
 
Statistical analysis 
Descriptive data are shown as absolute and relative frequencies of the different modalities for 
categorical data; as median and interquartile range (IQR) for continuous variables. Chi-square test 
for categorical variables and Wilcoxon test for independent data for continuous variables were 
carried out to assess whether significant differences could be demonstrated between time periods 
(before and after 2010).  
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Due to the observed differences in patients' characteristics between time periods, a propensity score 
analysis was carried out using a logistic regression model with time period as outcome. In the 
propensity score model, patient’s characteristics which resulted associated with the time period 
(obesity,  hypercholesterolemia, anterior location and transfer from other hospitals) were entered in 
the model.  
Validation of the model was done through graphical examination of the residual diagnostics. 
Discrimination Index D (the higher the better) and the Somer's concordance index Dxy (the closer 
to 1 the better) were also computed. In absence of an external data source for model validation, to 
account for the degree of optimism in model accuracy induced by the use of the same data for 
training and testing purposes, goodness of fit indexes were computed using bootstrap (20 runs). 
Checking of the balance after the matching was performed using Chi-square and t test. Using 
individual propensity score, 876 patients in time period 2010-2013 were matched to 876 patients in 
time period 2003-2009;  a caliper size equal to one-fifth of the standard deviation of the logit of the 
estimated propensity score was used. Finally, the analysis of the propensity score-matched sample 
was carried out using conditional logistic regression model, which accounts for correlation within 
matched pairs, including variables: period (pre-post 2010), hypercholesterolemia and total ischemic 
time (superior vs inferior to 3h). All tests were performed at a significance level of 5%. Analyses 
were done with R version 3.02 (R Core Team, Wien, Austria). 
Results 
From March 2003 to December 2013 1980 patients with STEMI underwent PPCI in our 
catheterization laboratory, whose 1078 in P1  and 902 in P2. The clinical characteristics of the two 
groups are shown in table 1. The patients of P2 were significantly more obese (body mass index ≥ 
30 Kg per square meter), hypercholesterolemic, more likely to be transferred from another hospital 
without PCI facility and presented lower rate of anterior infarction. Furthermore, patients of P2 had 
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a significant longer D2B time and a lower rate of them underwent PPCI within 3 hours from the 
beginning of the symptoms.  
Procedural characteristics are depicted in figure 1 showing a significant increase of TRA in P2, 
along with the use of bivalirudin, new antiplatelet drugs and DES implantation. In parallel, in the 
same period, the use of GP IIb-IIIa and of IABP significantly decreased. Furthermore, the rate of 
TA and multivessel PCI did not significantly change (table 2).  
At 30-days (table 3) a significant increase of the procedural efficacy (from 95.1 to 97.2% , p=0.01) 
as well as a significant decrease of in-hospital mortality (from 6.3% to 3.9%, p=0.01), of ST (from 
1.3 to 0.4%, p= 0.046) and of overall MACE (from 6.9% to 4.2%, p=0.01) occurred in P2 as 
compared to P1. The rate of bleeding complications remained almost unchanged (from 2.2% to 
2.0%, p=0.7). Before matching with the propensity score (figure 2), the efficacy of the procedure 
was significantly associated to P2 (OR 1.81, CI 95%, 1.12-2.94) as well as MACE and mortality at 
30 days resulted significantly reduced after 2010 (in P2). Logistic regression analyses on matched 
patients confirmed the before matching results for the efficacy of the procedure (OR 2.09, CI 95%, 
1.04-4.21, figure 3), whereas MACE and mortality at 30 days did not result significantly associated 
to the time perdiod anymore. Moreover ST showed a trend towards a significant reduction (OR 0.3; 
0.09-1.03).  
 
Discussion 
Our large observational registry showed that, after 2010, the current practice of PPCI in our centre 
significantly changed, with a significant increase of TRA, of the use of either bivalirudin or new 
antiplatelet drugs or DES and a significant decrease of the use of either GP IIb-IIIa inhibithors and 
IABP, whereas the rates of TA and multivessel PCI remained almost unchanged. Despite the 
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significant increase of the D2B time and the decrease of the number of the patients who underwent 
PPCI within 3 hours from the beginning of the symptoms (probably due to the widening of the 
catchment area), there was a significant increase of the efficacy of the procedure and a trend 
towards the significance of the reduction of ST. Our findings are in agreement either with 
randomized or non-randomized studies 
5–10
 or large registries 
21–25
.  Moreover, our study did not 
show significant differences in bleedings between the two study periods. This finding can further 
support the hypothesis that the decrease of cardiovascular events related to TRA and bivalirudin use 
can go beyond the simple reduction of bleeding complications 
26,27
. More recent Unfractionated 
heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI) 
randomized trial 
28
, has raised concerns with regard to the increase of acute ST and even of the 
mortality. As a result, the last guidelines downgraded the bivalirudin use to a IIa class 
29
. We did 
not find this relationship but rather a reduction, although not significant, of ST. The longer period of 
infusion at higher concentration, as stated by the EUROMAX 
17
 randomized trial, the use of new 
antiplatelet drugs and the UFH  bolus given in emergency room or in ambulance, that has already 
shown to reduce the composite endpoint of death and ST compared to bivalirudin alone 
30
, can have 
overcome this negative effect.  
Limitations 
Our study offers the advantages and limitations of carefully performed observational registries: 
first, it is a retrospective analysis and is therefore subject to the limitations of such analyses. In 
particular, the procedural increase and decrease in rates of MACE cannot be attributed to a specific 
covariate. As a matter of fact our work was not powered, to find differences in the clinical 
outcomes, either because of the relatively small number of the patients, or of the non-randomized 
nature of the study. Secondly, the addition of a referral source with an intensive cardiac care unit 
but not PCI capability, could have somewhat changed significantly the referral population. For this 
reason, propensity score matching further enhanced the comparability of the patients..Third, the 
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data are derived from a single center, which limits their applicability. Finally, we analyzed only the 
30-days oucomes. Therefore, it is not possible to extend the results beyond the acute phase. 
Conclusions 
Our large retrospective registry shows that in the last years, after the publication of pivotal 
randomized trial and large registries, there were significant changes in the current practice of 
primary PCI in a high primary PCI-volume catheterization laboratory, in particular either the 
increase of the TRA, bivalirudin, new antiplatelet drugs and DES, or the decrease of IABP and GP 
IIb-IIIa, These changes could have had an impact on procedural efficacy. However, due to the 
single centre retrospective evaluation, these findings need to be confirmed by further studies. 
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Figure legend 
Figure 1. Temporal changes trend in procedural characteristics between 2003 and 2013. Vertical 
axis represents the percentage of cases. DES: Drug Eluting Stents; IABP: Intra Aortic Balloon 
Pump;  New Antiplatelet Drugs:  Prasugrel or Ticagrelor 
Figure 2. Multiple logistic regression analysis. OR: Odds Ratio; MACE: Major Adverse Cardiac 
Events 
Figure 3. Individual propensity score matching analysis. OR: Odds Ratio; MACE: Major Adverse 
Cardiac Events 
 
 Net benefit effect demonstrated in randomized clinical trials (RCT) might not be the same as 
that observed in different clinical settings. Large observational registries are needed in order 
to assessing treatment effectiveness in patients encountered in day-to-day clinical practice, 
undergoing everyday therapy. 
 After the publication of pivotal randomized trial and large registries, there were significant 
changes in the current practice of primary PCI in a high primary PCI-volume catheterization 
laboratory. 
 We reported an increase of the trans-radial approach, of the use of either bivalirudin or new 
antiplatelet drugs or DES and a significant decrease of the use of either GP IIb-IIIa 
inhibithors and IABP. Conversely the rates of manual thrombus aspiration and multivessel 
PCI remained almost unchanged. 
 These changes could have had an impact on procedural efficacy 
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Table I. General Characteristics 
 
 P1 (2003-2009) P2 (2010-2015) p Value 
Number of patients 1078 902  
Male Gender 801 (74.4) 695 (77.1) 0.17 
Age (years)* 66 (56-75)* 65 (56-75)* 0.37 
Age≥80 years 139 (12.9) 123 (13.6) 0.63 
Transferred from another hospital 248 (23) 290 (32.2) <0.001 
Current Smokers 323 (30.0) 307 (34.4) 0.053 
Hypertension 738 (68.5) 632 (70.1) 0.47 
Hypercholesterolemia 324 (30.1) 418 (46.3) <0.001 
Diabetes 243 (22.5) 224 (24.8) 0.73 
Obesity^ 142 (13.2) 165 (18.3) 0.002 
Renal Failure§ 33 (3.1) 20 (2.2) 0.25 
Anterior Infarction 490 (46.8) 357 (40.8) 0.008 
LVEF (%)
#
 48.1±9.6** 48.9±8.3** 0.87 
Killip Class ≥3 118 (11.0) 84 (9.3) 0.23 
Symptom onset-to-door time (min) 121 (68-267)* 120 (72-239)* 0.64 
Door-to-Balloon time (min) 59 (36-98)* 76 (53-119)* <0.001 
Total ischemic time≥3 hours 383 (55.9) 518 (61.6) 0.025 
 
Data are n (%) unless otherwise stated. 
* Median (interquartiles ranges) 
** Mean ± SD  
^ Body Mass Index ≥30 
§ Renal failure defined as baseline creatinine ≥ 2.5 mg/deciliter. 
# Left Ventricular Ejection Fraction 
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Table II. Angiographic Findings and Procedural 
Characteristics 
 
 P1 (2003-2009) P2 (2010-2013) P Value 
Number of patients 1078 902  
Multivessel Disease 558 (52.0) 486 (54.1) 0.11 
Radial Access 17 (1.5) 308 (34.1) <0.001 
Bivalirudin 5 (0.5) 205 (22.7) <0.001 
GP IIb-IIIa Inhibitors 887 (82.3) 469 (52.0) <0.001 
IABP 183 (17.0) 68 (7.5) <0.001 
Multivessel PCI 55 (5.2) 36 (4.0) 0.28 
Thrombus Aspiration 601 (55.8) 500 (55.4) 0.89 
DES 120 (11.1) 138 (15.3) 0.006 
New Antiplatelet Drugs* 0 165 (18.3) <0.001 
    
    
Data are n (%) unless otherwise stated 
IABP = Intra Aortic Balloon Pump 
DES = Drug-Eluting Stents 
*Prasugrel or Ticagrelor
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Table III. 30-Days outcomes 
 
 P1 (2003-2009) P2 (2010-2013) P Value 
Number of patients 1078 902  
Efficacy of the procedure* 1025 (95.1) 877 (97.2) 0.015 
In-Hospital Death 68 (6.3) 35 (3.9) 0.015 
Bleeding Complications**  24 (2.2) 18 (2.0) 0.72 
Re-AMI 1 (0.1) 2 (0.2) 0.46 
Target Vessel Revascularization 5 (0.5) 1 (0.1) 0.15 
Mechanical Complications 14 (1.3) 5 (0.6) 0.11 
Stroke  6 (0.6) 2 (0.2) 0.30 
MACEs 74 (6.9) 38 (4.2) 0.01 
Stent Thrombosis§ 14 (1.3) 4 (0.4) 0.046 
    
    
Data are n (%) unless otherwise stated 
*TIMI 3 grade flow and residual stenosis ≤ 30% 
**BARC ≥ 3 
MACEs = Major Adverse Cardiac Events 
§ Acute and Subacute 
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